GT201200265A - Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar - Google Patents
Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliarInfo
- Publication number
- GT201200265A GT201200265A GT201200265A GT201200265A GT201200265A GT 201200265 A GT201200265 A GT 201200265A GT 201200265 A GT201200265 A GT 201200265A GT 201200265 A GT201200265 A GT 201200265A GT 201200265 A GT201200265 A GT 201200265A
- Authority
- GT
- Guatemala
- Prior art keywords
- peptide
- coupled
- amiloid
- viruses
- beta
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 238000010276 construction Methods 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 241001515965 unidentified phage Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158273 | 2010-03-29 | ||
| US36169710P | 2010-07-06 | 2010-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201200265A true GT201200265A (es) | 2014-03-14 |
Family
ID=42285305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201200265A GT201200265A (es) | 2010-03-29 | 2012-09-26 | Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20130011431A1 (enExample) |
| EP (1) | EP2552489A1 (enExample) |
| JP (2) | JP6088422B2 (enExample) |
| KR (1) | KR20130018407A (enExample) |
| CN (2) | CN102834118A (enExample) |
| AR (1) | AR080810A1 (enExample) |
| AU (1) | AU2011234656B2 (enExample) |
| BR (1) | BR112012024708A2 (enExample) |
| CA (1) | CA2793580A1 (enExample) |
| CL (1) | CL2012002685A1 (enExample) |
| CO (1) | CO6630127A2 (enExample) |
| EC (1) | ECSP12012180A (enExample) |
| GT (1) | GT201200265A (enExample) |
| IL (1) | IL221540B (enExample) |
| MA (1) | MA34084B1 (enExample) |
| MX (1) | MX2012011340A (enExample) |
| NZ (1) | NZ601729A (enExample) |
| PE (1) | PE20130642A1 (enExample) |
| PH (1) | PH12012501683A1 (enExample) |
| RU (1) | RU2603486C2 (enExample) |
| SG (2) | SG10201505374TA (enExample) |
| TN (1) | TN2012000431A1 (enExample) |
| TW (2) | TW201138805A (enExample) |
| WO (1) | WO2011120924A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3027205A4 (en) | 2013-07-28 | 2017-07-19 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| WO2015165971A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| DK3137094T3 (da) * | 2014-04-29 | 2023-02-27 | Advantage Therapeutics Inc | Behandling og forebyggelse af alzheimers sygdom (ad) |
| KR102388363B1 (ko) * | 2014-04-29 | 2022-04-19 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| JP2017514831A (ja) * | 2014-04-29 | 2017-06-08 | アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ | アルツハイマー病（ａｄ）の処置および予防 |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| MX2022002980A (es) | 2019-09-16 | 2022-04-06 | Amgen Inc | Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos. |
| WO2026155574A1 (ko) * | 2025-01-15 | 2026-07-23 | 주식회사 포스백스 | 파필로마바이러스 바이러스 유사입자 기반 항-아밀로이드 베타 동물용 백신 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
| CA2295740A1 (en) * | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| CN100350972C (zh) * | 2001-07-26 | 2007-11-28 | 启龙股份公司 | 含有铝佐剂和组氨酸的疫苗 |
| BR0312792A (pt) | 2002-07-19 | 2005-05-03 | Cytos Biotechnology Ag | Composições de vacinas contendo séries antigênicas de amilóide beta1-6 |
| CN100409896C (zh) * | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
| NZ554387A (en) * | 2004-09-21 | 2009-09-25 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| CN101318015A (zh) * | 2008-06-25 | 2008-12-10 | 中山大学 | 老年性痴呆重组蛋白疫苗及其制备方法 |
-
2011
- 2011-03-28 JP JP2013501791A patent/JP6088422B2/ja not_active Expired - Fee Related
- 2011-03-28 TW TW100110650A patent/TW201138805A/zh unknown
- 2011-03-28 MX MX2012011340A patent/MX2012011340A/es active IP Right Grant
- 2011-03-28 AU AU2011234656A patent/AU2011234656B2/en not_active Ceased
- 2011-03-28 CA CA2793580A patent/CA2793580A1/en not_active Abandoned
- 2011-03-28 SG SG10201505374TA patent/SG10201505374TA/en unknown
- 2011-03-28 PH PH1/2012/501683A patent/PH12012501683A1/en unknown
- 2011-03-28 WO PCT/EP2011/054735 patent/WO2011120924A1/en not_active Ceased
- 2011-03-28 RU RU2012145734/15A patent/RU2603486C2/ru not_active IP Right Cessation
- 2011-03-28 EP EP11711322A patent/EP2552489A1/en not_active Withdrawn
- 2011-03-28 BR BR112012024708A patent/BR112012024708A2/pt not_active Application Discontinuation
- 2011-03-28 SG SG2012060554A patent/SG183806A1/en unknown
- 2011-03-28 NZ NZ601729A patent/NZ601729A/xx not_active IP Right Cessation
- 2011-03-28 PE PE2012001825A patent/PE20130642A1/es not_active Application Discontinuation
- 2011-03-28 TW TW104125184A patent/TW201618806A/zh unknown
- 2011-03-28 CN CN2011800162176A patent/CN102834118A/zh active Pending
- 2011-03-28 KR KR1020127025613A patent/KR20130018407A/ko not_active Ceased
- 2011-03-28 MA MA35241A patent/MA34084B1/fr unknown
- 2011-03-28 CN CN201410789825.6A patent/CN104436212A/zh active Pending
- 2011-03-28 US US13/578,017 patent/US20130011431A1/en not_active Abandoned
- 2011-03-28 AR ARP110101001A patent/AR080810A1/es not_active Application Discontinuation
-
2012
- 2012-08-20 IL IL221540A patent/IL221540B/en not_active IP Right Cessation
- 2012-08-30 TN TNP2012000431A patent/TN2012000431A1/en unknown
- 2012-09-25 EC ECSP12012180 patent/ECSP12012180A/es unknown
- 2012-09-26 GT GT201200265A patent/GT201200265A/es unknown
- 2012-09-27 CL CL2012002685A patent/CL2012002685A1/es unknown
- 2012-10-01 CO CO12171902A patent/CO6630127A2/es unknown
-
2014
- 2014-08-11 US US14/456,562 patent/US20140348871A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,492 patent/US20150297692A1/en not_active Abandoned
- 2015-12-17 US US14/972,187 patent/US20160101167A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115660A patent/JP2017008035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6630127A2 (es) | Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar | |
| DOP2019000201A (es) | Compuestos inhibidores del vih | |
| CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
| DOP2016000233A (es) | MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B | |
| CL2012002355A1 (es) | Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih. | |
| AR091395A1 (es) | Aminotriazolopiridina para usar el tratamiento de la inflamacion y composiciones farmaceuticas de la misma | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
| CU20150071A7 (es) | Composición de liberación demorada que comprende biguanida | |
| UY33897A (es) | Inhibidores del virus de la hepatitis c | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| CU20180035A7 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| CU20170161A7 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| MX2012000389A (es) | Imidazoles fusionados y composiciones que los comprenden para el tratamiento de enfermedades parasitarias, tales como, por ejemplo, malaria. | |
| UA108858C2 (xx) | Похідні ізоксалідину | |
| HN2011000864A (es) | Particulas inhalables que comprenden tiotropio | |
| CL2017001275A1 (es) | Análogos ligados de urea sustituidos como moduladores de sirtuina | |
| MX2017004359A (es) | Composiciones farmaceuticas que comprenden alpelisib. | |
| CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| BR112012022209A2 (pt) | composições farmacêuticas compreendendo monoterpenos | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| CL2016000300A1 (es) | Métodos terapéuticos | |
| MX2017008983A (es) | Composición farmaceútica de sulfonamida. | |
| EA201590678A1 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |